Genedrive Regulatory News (GDR)

RNS Press Release

For release: 19 February 2016

Update on CEO Appointment

Epistem Holdings Plc (LSE: EHP), the personalised medicine and biotechnology company, is pleased to announce that, following his appointment as Chief Executive Officer and as Board Director as announced on 13 January 2016, David Budd will join Epistem on 1 March 2016.

David has over 20 years of international commercial and operational experience in the diagnostics and medical devices field, launching multiple diagnostics products into international markets. He joins from Leica Biosystems (a Danaher company), a fast growing organisation where he served as General Manager of Leica Biosystems Amsterdam. David previously served as Commercial Director at Leica Biosystems Newcastle, with global responsibility for marketing, market research and product launches for diagnostic tests.

Prior to joining Leica Biosystems, David's previous roles included Point-of-Care, molecular, and central laboratory marketing and commercialization responsibilites as a Director of Marketing at Siemens Healthcare Diagnostics, Business Unit Leader at Bayer Diagnostics UK, and Sales Manager at Visible Genetics Inc.

- Ends -

For further details please contact:

Epistem Holdings Plc

Dr Ian Gilham: Chairman +44 (0)161 606 7258

John Rylands: Finance Director

Peel Hunt LLP

James Steel +44 (0)207 418 8900

Tom Burt

Oliver Jackson

Consilium Strategic Communications

Chris Gardner +44 (0)203 709 5700

Laura Thornton

epistem@consilium-comms.com 

Notes to Editors

Epistem is a personalised medicine and biotechnology company developing innovative diagnostics and biomarkers alongside providing contract research services to drug development companies. Epistem's Genedrive® is a next-generation Point of Care molecular diagnostic system providing a low cost, rapid, versatile, simple to use and robust diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Genedrive® aims to provide a 'gold standard' identification of Tuberculosis & antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid and molecular tests for Tuberculosis into their disease testing programs. The Genedrive® platform and its first Tuberculosis test is now being prepared for launch in India and the Indian sub-continent. Further details can be found at: www.epistem.co.uk and www.genedrive.com